skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: MAGE genes: Prognostic indicators in AL amyloidosis patients

Authors:
ORCiD logo [1];  [1];  [1];  [1]; ORCiD logo [1]; ORCiD logo [2];  [1];  [3]
  1. Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China
  2. Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China, Peking‐Tsinghua Center for Life Sciences Academy for Advanced Interdisciplinary Studies, Peking University Beijing China, Collaborative Innovation Center of Hematology Soochow University Suzhou China
  3. Peking University People's Hospital, Peking University Institute of Hematology Beijing China, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China, Collaborative Innovation Center of Hematology, Peking University Beijing China, Collaborative Innovation Center of Hematology Soochow University Suzhou China
Publication Date:
Sponsoring Org.:
USDOE Office of Electricity Delivery and Energy Reliability (OE), Power Systems Engineering Research and Development (R&D) (OE-10)
OSTI Identifier:
1560211
Alternate Identifier(s):
OSTI ID: 1560212
Grant/Contract Number:  
[2017YFA0104500]]
Resource Type:
Published Article
Journal Name:
Journal of Cellular and Molecular Medicine
Additional Journal Information:
[Journal Name: Journal of Cellular and Molecular Medicine Journal Volume: 23 Journal Issue: 8]; Journal ID: ISSN 1582-1838
Publisher:
Wiley-Blackwell
Country of Publication:
Country unknown/Code not available
Language:
English

Citation Formats

Liu, Yang, Wen, Lei, Ma, Ling, Kang, Ying, Liu, Kai‐Yan, Huang, Xiao‐Jun, Ruan, Guo‐Rui, and Lu, Jin. MAGE genes: Prognostic indicators in AL amyloidosis patients. Country unknown/Code not available: N. p., 2019. Web. doi:10.1111/jcmm.14475.
Liu, Yang, Wen, Lei, Ma, Ling, Kang, Ying, Liu, Kai‐Yan, Huang, Xiao‐Jun, Ruan, Guo‐Rui, & Lu, Jin. MAGE genes: Prognostic indicators in AL amyloidosis patients. Country unknown/Code not available. doi:10.1111/jcmm.14475.
Liu, Yang, Wen, Lei, Ma, Ling, Kang, Ying, Liu, Kai‐Yan, Huang, Xiao‐Jun, Ruan, Guo‐Rui, and Lu, Jin. Thu . "MAGE genes: Prognostic indicators in AL amyloidosis patients". Country unknown/Code not available. doi:10.1111/jcmm.14475.
@article{osti_1560211,
title = {MAGE genes: Prognostic indicators in AL amyloidosis patients},
author = {Liu, Yang and Wen, Lei and Ma, Ling and Kang, Ying and Liu, Kai‐Yan and Huang, Xiao‐Jun and Ruan, Guo‐Rui and Lu, Jin},
abstractNote = {},
doi = {10.1111/jcmm.14475},
journal = {Journal of Cellular and Molecular Medicine},
number = [8],
volume = [23],
place = {Country unknown/Code not available},
year = {2019},
month = {6}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: 10.1111/jcmm.14475

Save / Share:

Works referenced in this record:

Immunotherapy for the treatment of multiple myeloma
journal, March 2017


Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation
journal, July 2017

  • Muchtar, Eli; Dispenzieri, Angela; Lacy, Martha Q.
  • British Journal of Haematology, Vol. 178, Issue 6
  • DOI: 10.1111/bjh.14830

The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma
journal, January 2014


Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
journal, July 2017


Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected?
journal, July 2017

  • Chim, Chor S.
  • British Journal of Haematology, Vol. 178, Issue 6
  • DOI: 10.1111/bjh.14835

Correlates of immune and clinical activity of novel cancer vaccines
journal, October 2018


The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients
journal, November 2014

  • Huang, X.; Wang, Q.; Jiang, S.
  • Clinical Kidney Journal, Vol. 8, Issue 1
  • DOI: 10.1093/ckj/sfu117

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
journal, January 2017


Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
journal, November 2011


Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain–associated amyloidosis (AL)
journal, May 2003


Treatment of Immunoglobulin Light Chain Amyloidosis
journal, August 2015


Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma
journal, February 2009


New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
journal, December 2012

  • Palladini, Giovanni; Dispenzieri, Angela; Gertz, Morie A.
  • Journal of Clinical Oncology, Vol. 30, Issue 36
  • DOI: 10.1200/JCO.2011.37.7614

MAGE-C2/CT10 Protein Expression Is an Independent Predictor of Recurrence in Prostate Cancer
journal, July 2011


Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma
journal, October 2010

  • Pabst, Caroline; Zustin, Jozef; Jacobsen, Frank
  • Experimental and Molecular Pathology, Vol. 89, Issue 2
  • DOI: 10.1016/j.yexmp.2010.06.011

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
journal, May 2016


Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains
journal, September 2017


Cancer-testis antigen expression and immunogenicity in AL amyloidosis
journal, September 2012

  • Rosenzweig, M. A.; Landau, H.; Seldin, D.
  • Blood Cancer Journal, Vol. 2, Issue 9
  • DOI: 10.1038/bcj.2012.32

Is immunotherapy here to stay in multiple myeloma?
journal, January 2017


Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
journal, April 2012


Cancer testis antigen MAGE C1 can be used to monitor levels of circulating malignant stem cells in the peripheral blood of multiple myeloma patients
journal, August 2016

  • Shires, Karen; Wienand, Kirsty
  • Journal of Cancer Research and Clinical Oncology, Vol. 142, Issue 11
  • DOI: 10.1007/s00432-016-2231-3

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells
journal, December 2009


International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
journal, November 2014


Genome-wide analysis of cancer/testis gene expression
journal, December 2008

  • Hofmann, O.; Caballero, O. L.; Stevenson, B. J.
  • Proceedings of the National Academy of Sciences, Vol. 105, Issue 51
  • DOI: 10.1073/pnas.0810777105

T cell-based targeted immunotherapies for patients with multiple myeloma: Immunotargets in MM patients
journal, September 2014

  • Wang, Lei; Jin, Nan; Schmitt, Anita
  • International Journal of Cancer, Vol. 136, Issue 8
  • DOI: 10.1002/ijc.29190

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy
journal, November 2012

  • de Carvalho, Fabricio; Alves, Veruska L. F.; Braga, Walter M. T.
  • Cancer Immunology, Immunotherapy, Vol. 62, Issue 1
  • DOI: 10.1007/s00262-012-1376-4